Lipid Disorders
Conference Coverage
EASD: Studies slam cardiovascular safety of sulfonylureas
Sulfonylureas seem to increase substantially the risk for cardiovascular events relative to other antihyperglycemic agents.
Conference Coverage
Sleeve gastrectomy cut biochemical cardiac risk factors
Many traditional and novel biochemical cardiac risk markers show dramatic and stable improvements following sleeve gastrectomy, a prospective,...
Conference Coverage
EASD: Alirocumab lipid-lowering benefits extend to patients with high-risk diabetes
The benefits of alirocumab seen in the main study population extend to people with diabetes, with no risk for new onset or worsening of diabetes...
News
Metabolic monitoring of antipsychotic meds
Dr. Robert R. Althoff discusses how the prescription and monitoring of antipsychotic medication often falls to the primary care clinician.
News
Long-acting insulin degludec – and degludec combo drug – win FDA nod
Two new insulins have gained FDA approval.
Conference Coverage
EASD: SGLT2 inhibitor empagliflozin cuts CV risk in patients with type 2 diabetes
Key clinical point: Empagliflozin reduced cardiovascular risk in patients with type 2 diabetes who were at high cardiovascular risk, making it the...
Conference Coverage
Long-acting basal insulin controls HbA1c as well as glargine
Key clinical point: In patients with type 1 diabetes, treatment with the long-acting basal insulin peglispro conferred lower HbA1c with fewer...
Conference Coverage
ESC: Alirocumab ‘cures’ heterozygous familial hypercholesterolemia
The PCSK9 inhibitor alirocumab lowers LDL cholesterol to unprecedented levels in patients with heterozygous familial hypercholesterolemia.
News
ESC: MI survival of 40-somethings has improved dramatically
People younger than 50 years who had a MI during the 2000s had substantially better 10-year survival than younger adults who had a MI during the...
News
FDA warns of disabling joint pain from DPP-4 inhibitors
Most patients developed symptoms within a month of beginning treatment; however, some patients had been on a DPP-4 inhibitor for as long as a year...
News
Evolocumab is second PCSK9 inhibitor approved to lower LDL in high-risk patients
The FDA approves another PCSK9 inhibitor, evolocumab, an injectable, biologic lipid-lowering drug.